Skip to main content

Table 3 “Within Patient” analysis: Association between changes in gene signature and changes in disease activity between two visits from the same persona,b

From: Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus

 

IFN M1.2

IFN M3.4

IFN M5.12

BAFF

LDG

Plasma Cell

Estimate

(95% CI)

p value

Estimate

(95% CI)

p value

Estimate

(95% CI)

p value

Estimate

(95%CI)

p value

Estimate

(95% CI)

p value

Estimate

(95% CI)

p value

PGA

0.11

(− 0.03, 0.25)

0.12

0.09

(− 0.02, 0.19)

0.10

0.05

(− 0.04, 0.15)

0.28

0.02

(− 0.06, 0.10)

0.64

− 0.06

(− 0.17, 0.05)

0.29

0.07

(− 0.01, 0.15)

0.074

SLEDAI

0.35

(− 0.26, 0.97)

0.26

0.31

(−0.15, 0.77)

0.18

0.29

(−0.13, 0,71)

0.17

0.16

(−0.20, 0.53)

0.38

−0.06

(− 0.54, 0.42)

0.80

0.45

(0.10, 0.80)

0.011

SLEDAI Vascular

0.02

(−0.01, 0.06)

0.25

0.01

(−0.01, 0.04)

0.34

0.01

(−0.02, 0.03)

0.45

0.01

(−0.01, 0.03)

0.33

−0.00

(− 0.03, 0.03)

0.97

0.01

(− 0.01, 0.03)

0.27

SLEDAI MUSCULOSKELETAL

0.02

(−0.03, 0.07)

0.36

0.02

(−0.02, 0.06)

0.34

0.01

(−0.02, 0.05)

0.41

0.01

(−0.02, 0.04)

0.58

−0.01

(− 0.05, 0.03)

0.65

0.01

(− 0.02, 0.04)

0.65

SLEDAI Renal

0.03

(−0.06, 0.11)

0.54

0.03

(−0.03, 0.09)

0.36

0.05

(−0.01, 0.11)

0.078

0.02

(−0.03, 0.07)

0.36

0.03

(−0.03, 0.10)

0.33

0.02

(−0.03, 0.06)

0.54

SLEDAI Skin

−0.03

(− 0.11, 0.06)

0.53

− 0.00

(− 0.07, 0.06)

0.88

−0.02

(− 0.07, 0.04)

0.60

−0.04

(− 0.09, 0.01)

0.15

0.03

(− 0.03, 0.10)

0.31

0.02

(− 0.02, 0.07)

0.31

SLEDAI Hematologic

−0.04

(− 0.07, − 0.01)

0.0095

−0.03

(− 0.05, − 0.01)

0.0096

−0.03

(− 0.05, − 0.01)

0.014

−0.02

(− 0.04, − 0.00)

0.028

−0.03

(− 0.06, − 0.01)

0.0060

0.01

(− 0.02, 0.03)

0.36

SLEDAI Immunology

0.00

(− 0.08, 0.09)

0.92

0.00

(− 0.06, 0.06)

0.96

−0.02

(− 0.08, 0.03)

0.42

0.00

(− 0.05, 0.05)

0.97

−0.08

(− 0.14, − 0.01)

0.026

0.09

(0.04, 0.14)

0.0002

Urine Protein Creatinine Ratio

0.06

(−0.07, 0.19)

0.36

0.05

(−0.05, 0.15)

0.32

0.05

(−0.04, 0.13)

0.31

0.06

(−0.02, 0.14)

0.12

−0.04

(− 0.14, 0.06)

0.44

0.05

(− 0.02, 0.13)

0.17

Log Anti-dsDNA

0.05

(−0.16, 0.25)

0.65

0.05

(−0.10, 0.20)

0.52

−0.01

(− 0.15, 0.13)

0.94

0.03

(− 0.09, 0.15)

0.65

−0.05

(− 0.21, 0.11)

0.56

0.20

(0.08, 0.32)

0.0008

C3

1.28

(− 3.56, 6.11)

0.60

1.99

(− 1.66, 5.63)

0.28

2.57

(−0.75, 5.88)

0.13

−0.20

(− 3.07, 2.67)

0.89

5.71

(1.90, 9.51)

0.0034

−3.60

(− 6.38, − 0.81)

0.011

C4

0.73

(−0.35, 1.82)

0.18

0.52

(−0.30, 1.34)

0.21

0.57

(−0.18, 1.31)

0.14

0.18

(−0.47, 0.83)

0.58

1.05

(0.19, 1.90)

0.017

−1.39

(−2.01, −0.77)

< 0.0001

ESR

2.19

(− 1.17, 5.55)

0.20

2.25

(−0.28, 4.78)

0.082

2.43

(0.13, 4.73)

0.039

−0.14

(−2.15, 1.87)

0.89

2.05

(−0.63, 4.73)

0.13

3.75

(1.81, 5.70)

0.0002

  1. aThe entries in the table represent the expected change in disease activity measure per 1 standard deviation change in the gene signature. Bolded enteries had p-values less than 0.05
  2. bAll the associations are adjusted for prednisone use, age, sex and race
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us